Amgen’s ovarian cancer drug, Trebananib fails to pass 3rd survival trial phase
Amgen, the manufacturers of an ovarian cancer drug, Trebananib, are disappointed in the performance of the drug at its late-state third trial phase. Trebananib is supposed to be used alongside Paclitaxel, a che...